logo

Alkermes Plc (ALKS)



Trade ALKS now with
  Date
  Headline
10/23/2018 7:15:22 AM Alkermes plc (ALKS) Has Raised Its FY18 Revenue Estimate To $1015 - $1045 Mln From $975 - $1025 Mln
10/23/2018 7:02:58 AM Alkermes Plc Q3 Net Loss Narrows To $34.4 Mln Or $0.22/shr From $36.3 Mln Or $0.24/shr Last Year
10/17/2018 7:02:38 AM Alkermes Announces Presentation Of 10 Posters At Upcoming 31st Annual Psych Congress
9/10/2018 7:01:56 AM Alkermes Initiates Clinical Evaluation Of ALKS 4230 In Combination With PD-1 Inhibitor Pembrolizumab
7/26/2018 7:07:24 AM Alkermes Q2 Loss Per Share $0.21 Vs Loss $0.28 Last Year
7/2/2018 7:02:33 AM Alkermes: FDA Approves ARISTADA INITIO For Initiation Of ARISTADA For Schizophrenia
6/6/2018 7:03:18 AM Alkermes Gets $50 Mln Payment From Biogen Following Review Of Preliminary Gastrointestinal Tolerability Data